175 related articles for article (PubMed ID: 24703231)
1. Buthionine sulfoximine diverts the melanogenesis pathway toward the production of more soluble and degradable pigments.
Galván I; Wakamatsu K; Alonso-Alvarez C; Solano F
Bioorg Med Chem Lett; 2014 May; 24(9):2150-4. PubMed ID: 24703231
[TBL] [Abstract][Full Text] [Related]
2. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice.
Reliene R; Schiestl RH
Carcinogenesis; 2006 Feb; 27(2):240-4. PubMed ID: 16162646
[TBL] [Abstract][Full Text] [Related]
3. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561
[TBL] [Abstract][Full Text] [Related]
4. Buthionine sulfoximine is a multitarget inhibitor of trypanothione synthesis in Trypanosoma cruzi.
Vázquez C; Mejia-Tlachi M; González-Chávez Z; Silva A; Rodríguez-Zavala JS; Moreno-Sánchez R; Saavedra E
FEBS Lett; 2017 Dec; 591(23):3881-3894. PubMed ID: 29127710
[TBL] [Abstract][Full Text] [Related]
5. Glutathione homeostasis in human hepatic cells: overexpression of gamma-glutamylcysteine synthetase gene in cell lines resistant to buthionine sulfoximine, an inhibitor of glutathione synthesis.
Tanaka T; Uchiumi T; Kohno K; Tomonari A; Nishio K; Saijo N; Kondo T; Kuwano M
Biochem Biophys Res Commun; 1998 May; 246(2):398-403. PubMed ID: 9610371
[TBL] [Abstract][Full Text] [Related]
6. Buthionine sulfoximine embryotoxicity is associated with prolonged AP-1 activation.
Ozolins TR; Harrouk W; Doerksen T; Trasler JM; Hales BF
Teratology; 2002 Oct; 66(4):192-200. PubMed ID: 12353216
[TBL] [Abstract][Full Text] [Related]
7. [Effect of D,L-buthionine-S,R-sulfoximine on the ratio of glutathione forms and the growth of tatar buckwheat calli].
Nigmatullina LR; Rumiantseva NI; Kostiukova IuA
Ontogenez; 2014; 45(1):50-62. PubMed ID: 25720265
[TBL] [Abstract][Full Text] [Related]
8. Effect of L-buthionine-(S,R)-sulphoximine, an inhibitor of gamma-glutamylcysteine synthetase on peroxynitrite- and endotoxic shock-induced vascular failure.
Cuzzocrea S; Zingarelli B; O'Connor M; Salzman AL; Szabó C
Br J Pharmacol; 1998 Feb; 123(3):525-37. PubMed ID: 9504394
[TBL] [Abstract][Full Text] [Related]
9. The effect of buthionine sulfoximine on the glutathione level in goldfish tissues.
Lushchak VI; Hermes-Lima M
Ukr Biokhim Zh (1999); 2005; 77(3):35-8. PubMed ID: 16566126
[TBL] [Abstract][Full Text] [Related]
10. Depletion of glutathione by L-buthionine sulfoximine does not promote inactivation of myo-inositol transport in cultured bovine lens epithelial cells.
Cammarata PR; Tse D; Yorio T
Curr Eye Res; 1991 Apr; 10(4):321-30. PubMed ID: 1676962
[TBL] [Abstract][Full Text] [Related]
11. Buthionine sulfoximine treatment impairs rat diaphragm function.
Morales CF; Anzueto A; Andrade F; Brassard J; Levine SM; Maxwell LC; Lawrence RA; Jenkinson SG
Am J Respir Crit Care Med; 1994 Apr; 149(4 Pt 1):915-9. PubMed ID: 7908245
[TBL] [Abstract][Full Text] [Related]
12. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
13. Utilization of 6-(methylsulfinyl)hexyl isothiocyanate for sensitization of tumor cells to antitumor agents in combination therapies.
Yamaguchi H; Kidachi Y; Kamiie K; Noshita T; Umetsu H; Fuke Y; Ryoyama K
Biochem Pharmacol; 2013 Aug; 86(4):458-68. PubMed ID: 23791871
[TBL] [Abstract][Full Text] [Related]
14. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331
[TBL] [Abstract][Full Text] [Related]
15. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ
Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766
[TBL] [Abstract][Full Text] [Related]
16. Glutathione: an overview of biosynthesis and modulation.
Anderson ME
Chem Biol Interact; 1998 Apr; 111-112():1-14. PubMed ID: 9679538
[TBL] [Abstract][Full Text] [Related]
17. Schisandrin B-induced increase in cellular glutathione level and protection against oxidant injury are mediated by the enhancement of glutathione synthesis and regeneration in AML12 and H9c2 cells.
Chiu PY; Ko KM
Biofactors; 2006; 26(4):221-30. PubMed ID: 17119269
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
Kable EP; Favier D; Parsons PG
Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
[TBL] [Abstract][Full Text] [Related]
19. The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation.
Drew R; Miners JO
Biochem Pharmacol; 1984 Oct; 33(19):2989-94. PubMed ID: 6148944
[TBL] [Abstract][Full Text] [Related]
20. The effect of in utero administration of buthionine sulfoximine on rat development.
Reyes E; Ott S; Robinson B; Contreras R
Pharmacol Biochem Behav; 1995 Apr; 50(4):491-7. PubMed ID: 7617692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
